Objectives: Amiodarone administration is presently considered in the prevention of new-onset postoperative atrial fibrillation (PAF) after cardiac operations, but relapse of PAF requiring anticoagulation therapy at ho...Objectives: Amiodarone administration is presently considered in the prevention of new-onset postoperative atrial fibrillation (PAF) after cardiac operations, but relapse of PAF requiring anticoagulation therapy at hospital discharge is prevalent despite amiodarone prophylaxis. PAF is also associated with increased morbidity and mortality including complications resulting from long-term anticoagulation therapy. Currently, the most effective therapy to prevent PAF after cardiac surgery remains undetermined. Inflammatory mechanisms may be partly responsible for PAF. Minocycline, a tetracycline antibiotic, has specifically an atrial myocytes anti-apoptotic effect, decreases right atrial tissue inflammation and oxidative stress activity. These observations led to this trial’s hypothesis that the addition of minocycline to amiodarone may favorably affect suppression of PAF. Methods: This trial compares the efficacy and safety of minocycline plus amiodarone versus amiodarone alone, in the prevention of PAF among adult patients undergoing cardiac procedures. All patients receive Beta-blocker agent. The primary outcome is PAF occurrence. Secondary outcomes include thromboembolic stroke, need for pharmacologic or electric cardioversion, mediastinal exploration for sepsis or for anticoagulation-related bleeding, serious drug side effects, length of hospital stay and 30-day mortality from cardiovascular causes. Results: This is an ongoing prospective single center randomized controlled clinical trial. Conclusion: The trial provides information on the comparative effectiveness of this low-risk prevention therapy of PAF that could be integrated in clinical practice. (Clinicaltrials.gov number, NCT 01422148).展开更多
目的探讨外科重症监护病房(surgical intensive care unit,SICU)内的非心脏手术患者围术期心血管事件与2年生存率的关系。方法回顾性分析北京大学第一医院2013年3月至2015年3月1753例因非心脏手术后入住SICU患者的病例资料。记录所有患...目的探讨外科重症监护病房(surgical intensive care unit,SICU)内的非心脏手术患者围术期心血管事件与2年生存率的关系。方法回顾性分析北京大学第一医院2013年3月至2015年3月1753例因非心脏手术后入住SICU患者的病例资料。记录所有患者的既往心血管病史,再收集术后重症病房住院期间新发心血管事件或既往心血管疾病加重的资料。所有患者转出重症医学科后予2年随访,统计分析其生存情况。结果截至转出重症医学科2年后,心血管病史组术后2年死亡率明显高于无心血管病史组(P=0.001),围术期出现心血管事件患者2年死亡率明显高于未出现围术期心血管事件患者(P<0.001)。多因素分析2年死亡率相关的独立危险因素包括既往冠状动脉粥样硬化性心脏病、围术期心力衰竭、围术期心肌缺血。结论非心脏手术SICU患者既往心血管病史及围术期心血管事件均会降低术后2年生存率,在治疗中应高度重视心血管疾病管理。展开更多
文摘Objectives: Amiodarone administration is presently considered in the prevention of new-onset postoperative atrial fibrillation (PAF) after cardiac operations, but relapse of PAF requiring anticoagulation therapy at hospital discharge is prevalent despite amiodarone prophylaxis. PAF is also associated with increased morbidity and mortality including complications resulting from long-term anticoagulation therapy. Currently, the most effective therapy to prevent PAF after cardiac surgery remains undetermined. Inflammatory mechanisms may be partly responsible for PAF. Minocycline, a tetracycline antibiotic, has specifically an atrial myocytes anti-apoptotic effect, decreases right atrial tissue inflammation and oxidative stress activity. These observations led to this trial’s hypothesis that the addition of minocycline to amiodarone may favorably affect suppression of PAF. Methods: This trial compares the efficacy and safety of minocycline plus amiodarone versus amiodarone alone, in the prevention of PAF among adult patients undergoing cardiac procedures. All patients receive Beta-blocker agent. The primary outcome is PAF occurrence. Secondary outcomes include thromboembolic stroke, need for pharmacologic or electric cardioversion, mediastinal exploration for sepsis or for anticoagulation-related bleeding, serious drug side effects, length of hospital stay and 30-day mortality from cardiovascular causes. Results: This is an ongoing prospective single center randomized controlled clinical trial. Conclusion: The trial provides information on the comparative effectiveness of this low-risk prevention therapy of PAF that could be integrated in clinical practice. (Clinicaltrials.gov number, NCT 01422148).
文摘目的探讨外科重症监护病房(surgical intensive care unit,SICU)内的非心脏手术患者围术期心血管事件与2年生存率的关系。方法回顾性分析北京大学第一医院2013年3月至2015年3月1753例因非心脏手术后入住SICU患者的病例资料。记录所有患者的既往心血管病史,再收集术后重症病房住院期间新发心血管事件或既往心血管疾病加重的资料。所有患者转出重症医学科后予2年随访,统计分析其生存情况。结果截至转出重症医学科2年后,心血管病史组术后2年死亡率明显高于无心血管病史组(P=0.001),围术期出现心血管事件患者2年死亡率明显高于未出现围术期心血管事件患者(P<0.001)。多因素分析2年死亡率相关的独立危险因素包括既往冠状动脉粥样硬化性心脏病、围术期心力衰竭、围术期心肌缺血。结论非心脏手术SICU患者既往心血管病史及围术期心血管事件均会降低术后2年生存率,在治疗中应高度重视心血管疾病管理。
